These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 3730698

  • 1. BW A256C, a chemically novel class 1 antiarrhythmic agent. A comparison of in vitro and in vivo activity with other class 1 antiarrhythmic agents.
    Allan G, Donoghue S, Follenfant MJ, Sawyer DA.
    Br J Pharmacol; 1986 Jun; 88(2):333-43. PubMed ID: 3730698
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effects of BW A256C, a novel class 1 antiarrhythmic agent, on maximum rate of depolarisation of cardiac action potentials in vitro: frequency, use, and voltage dependence.
    Donoghue S, Payne PN, Allan G.
    J Cardiovasc Pharmacol; 1987 Jan; 9(1):12-8. PubMed ID: 2434786
    [Abstract] [Full Text] [Related]

  • 4. Antiarrhythmic and hemodynamic effects of prifuroline.
    Benharkate M, Plassard G, Legeai J, Worcel M.
    Arzneimittelforschung; 1986 Dec; 36(12):1761-7. PubMed ID: 3566836
    [Abstract] [Full Text] [Related]

  • 5. Effects of AH-1058, a new antiarrhythmic drug, on experimental arrhythmias and cardiac membrane currents.
    Takahara A, Uneyama H, Sasaki N, Ueda H, Dohmoto H, Shoji M, Hara Y, Nakaya H, Yoshimoto R.
    J Cardiovasc Pharmacol; 1999 Apr; 33(4):625-32. PubMed ID: 10218734
    [Abstract] [Full Text] [Related]

  • 6. Electrophysiologic, antiarrhythmic, and cardioprotective effects of N-[3,5 dichlorophenyl] 4-[4-hydroxy-2-methoxy-phenyl] piperazine carboxamidine dihydrochloride (RS-87337).
    Dumez D, Patmore L, Ferrandon P, Allely M, Armstrong JM.
    J Cardiovasc Pharmacol; 1989 Aug; 14(2):184-93. PubMed ID: 2476590
    [Abstract] [Full Text] [Related]

  • 7. Effects of Org 7797 on early, late and inducible arrhythmias following coronary artery occlusion in rats and dogs.
    Winslow E, Campbell JK, Barron E, Marshall RJ, Muir AW.
    Br J Pharmacol; 1991 Dec; 104(4):853-8. PubMed ID: 1810599
    [Abstract] [Full Text] [Related]

  • 8. Actions of a newly synthesized compound (711389-S) on various types of experimentally induced arrhythmias in mammalian species in situ.
    Kadowaki Y, Ohta T, Hotokebuchi N, Kimoto S, Haruna M, Nakao T, Ueda M, Nishi K.
    Jpn J Pharmacol; 1988 Apr; 46(4):359-72. PubMed ID: 3404766
    [Abstract] [Full Text] [Related]

  • 9. Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory activity.
    Murakami M, Kinukawa M, Kanazawa T, Maruyama K, Miyagi M, Miyata H, Ujiie A.
    J Pharmacol Exp Ther; 1996 Nov; 279(2):877-83. PubMed ID: 8930195
    [Abstract] [Full Text] [Related]

  • 10. Lack of selectivity for ventricular and ischaemic tissue limits the antiarrhythmic actions of lidocaine, quinidine and flecainide against ischaemia-induced arrhythmias.
    Barrett TD, Hayes ES, Walker MJ.
    Eur J Pharmacol; 1995 Oct 24; 285(3):229-38. PubMed ID: 8575508
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Electrophysiologic, antiarrhythmic and hemodynamic effects of transcainide.
    Carmeliet E, Janssen PA, Heykants J, Niemegeers CJ, Remeysen P, Van De Water A, Van Gerven W, Wauquier A, Xhonneux R.
    Arch Int Pharmacodyn Ther; 1987 Jun 24; 287(2):272-90. PubMed ID: 3632145
    [Abstract] [Full Text] [Related]

  • 13. Pharmacological studies on propafenone and its main metabolite 5-hydroxypropafenone.
    von Philipsborn G, Gries J, Hofmann HP, Kreiskott H, Kretzschmar R, Müller CD, Raschack M, Teschendorf HJ.
    Arzneimittelforschung; 1984 Jun 24; 34(11):1489-97. PubMed ID: 6543124
    [Abstract] [Full Text] [Related]

  • 14. Antidysrhythmic and electrophysiological effects of a new antianginal agent, bepridil.
    Kane KA, Winslow E.
    J Cardiovasc Pharmacol; 1980 Jun 24; 2(2):193-203. PubMed ID: 6171686
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of antiarrhythmic agents and Mg2+ on aconitine-induced arrhythmias.
    Sawanobori T, Adaniya H, Hirano Y, Hiraoka M.
    Jpn Heart J; 1996 Sep 24; 37(5):709-18. PubMed ID: 8973383
    [Abstract] [Full Text] [Related]

  • 19. Antiarrhythmic, electrophysiologic and hemodynamic effects of lorcainide.
    Carmeliet E, Janssen PA, Marsboom R, Van Nueten JM, Xhonneux R.
    Arch Int Pharmacodyn Ther; 1978 Jan 24; 231(1):104-30. PubMed ID: 637616
    [Abstract] [Full Text] [Related]

  • 20. The Effect of a Novel Highly Selective Inhibitor of the Sodium/Calcium Exchanger (NCX) on Cardiac Arrhythmias in In Vitro and In Vivo Experiments.
    Kohajda Z, Farkas-Morvay N, Jost N, Nagy N, Geramipour A, Horváth A, Varga RS, Hornyik T, Corici C, Acsai K, Horváth B, Prorok J, Ördög B, Déri S, Tóth D, Levijoki J, Pollesello P, Koskelainen T, Otsomaa L, Tóth A, Baczkó I, Leprán I, Nánási PP, Papp JG, Varró A, Virág L.
    PLoS One; 2016 Jan 24; 11(11):e0166041. PubMed ID: 27832106
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.